Abstract
Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227 does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.
Keywords: Alpha-synuclein, brain, neuroimaging, small animal PET, synucleinopathies.
Current Alzheimer Research
Title:Binding of the PET Radiotracer [18F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice
Volume: 11 Issue: 10
Author(s): Elise Levigoureux, Sophie Lancelot, Caroline Bouillot, Fabien Chauveau, Mathieu Verdurand, Jeremy Verchere, Thierry Billard, Thierry Baron and Luc Zimmer
Affiliation:
Keywords: Alpha-synuclein, brain, neuroimaging, small animal PET, synucleinopathies.
Abstract: Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227 does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.
Export Options
About this article
Cite this article as:
Levigoureux Elise, Lancelot Sophie, Bouillot Caroline, Chauveau Fabien, Verdurand Mathieu, Verchere Jeremy, Billard Thierry, Baron Thierry and Zimmer Luc, Binding of the PET Radiotracer [18F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107154201
DOI https://dx.doi.org/10.2174/1567205011666141107154201 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Stem Cells, Self-Renewal and Cancer of the Gastric Epithelium
Current Medicinal Chemistry The Alzheimer's Disease-Related Glucose Metabolic Brain Pattern
Current Alzheimer Research Bipolar Affective Disorder, Epilepsy and Migraine – Does Possible Shared Pathogenesis Explain their Association?
Current Psychopharmacology Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors
Current Drug Targets Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Genomic and Molecular Characterization of Alzheimer Disease
Current Psychiatry Reviews Neurotransmitter Regulation of Adult Neurogenesis: Putative Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Neuromuscular Disorders in Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Cognitive Improvement by Photic Stimulation in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Cranial Ultrasound - Optimizing Utility in the NICU
Current Pediatric Reviews Identification of New Susceptibility Genes for Type 1 Diabetes: An Update
Current Immunology Reviews (Discontinued) ‘From Death, Lead Me to Immortality’ – Mantra of Ageing Skeletal Muscle
Current Genomics Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets